ATE350064T1 - Pharmazeutische zusammensetzungen von rapamycines - Google Patents

Pharmazeutische zusammensetzungen von rapamycines

Info

Publication number: ATE350064T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; rapamycines; ascomycin; prevention; reduction
Prior art date: 2001-04-04

Application number

AT02735219T

Other languages

English (en)

Inventor

Dorothea Ledergerber

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-04

Filing date

2002-04-03

Publication date

2007-01-15

2002-04-03 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2007-01-15 Application granted granted Critical

2007-01-15 Publication of ATE350064T1 publication Critical patent/ATE350064T1/de

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 abstract 1
ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 abstract 1
229920002678 cellulose Polymers 0.000 abstract 1
239000001913 cellulose Substances 0.000 abstract 1
239000013078 crystal Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT02735219T 2001-04-04 2002-04-03 Pharmazeutische zusammensetzungen von rapamycines ATE350064T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0108498.7A GB0108498D0 (en)	2001-04-04	2001-04-04	Organic Compounds

Publications (1)

Publication Number	Publication Date
ATE350064T1 true ATE350064T1 (de)	2007-01-15

Family

ID=9912264

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02735219T ATE350064T1 (de)	2001-04-04	2002-04-03	Pharmazeutische zusammensetzungen von rapamycines

Country Status (12)

Country	Link
US (3)	US20040171599A1 (de)
EP (1)	EP1377315B1 (de)
JP (1)	JP4927310B2 (de)
CN (2)	CN100358580C (de)
AT (1)	ATE350064T1 (de)
AU (1)	AU2002310920A1 (de)
BR (1)	BR0208655A (de)
CA (1)	CA2443235C (de)
DE (1)	DE60217315T2 (de)
GB (1)	GB0108498D0 (de)
PT (1)	PT1377315E (de)
WO (1)	WO2002080978A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060115522A1 (en) *	2003-02-17	2006-06-01	Cipla Ltd	Pharmaceutical composition
US20040185093A1 (en) *	2003-03-18	2004-09-23	Szymczak Christopher E.	Compositions containing sucralose
AU2005230401B2 (en)	2004-04-08	2008-11-27	Meda Pharma S.A.R.L.	Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
US20060062811A1 (en) *	2004-09-21	2006-03-23	Szymczak Christopher E	Medicinal cooling emulsions
GB0508827D0 (en) *	2005-04-29	2005-06-08	Novartis Ag	Cosmeceutical composition
KR101462474B1 (ko) *	2013-10-30	2014-11-19	주식회사 큐리언트	질레우톤 크림 제형의 국소용 항염증 약학적 조성물
US9855243B2 (en)	2013-10-30	2018-01-02	Qurient Co., Ltd.	Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation
EP3294294A4 (de) *	2015-05-08	2019-01-02	Vivus, Inc.	Zusammensetzungen und verfahren zur behandlung oder prävention von lungenhochdruck

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4127647A (en) *	1975-04-08	1978-11-28	Meiji Seika Kaisha, Ltd.	Process for preparation of stable amorphous macrolide antibiotic solids
GB8608080D0 (en) *	1986-04-02	1986-05-08	Fujisawa Pharmaceutical Co	Solid dispersion composition
IE66485B1 (en) *	1989-07-05	1996-01-10	Fujisawa Pharmaceutical Co	Aqueous liquid composition for external use
PH31204A (en) *	1990-11-02	1998-05-05	Fujisawa Pharmaceutical Co	Pharmaceutical composition.
IE65341B1 (en) *	1990-11-08	1995-10-18	Fujisawa Pharmaceutical Co	Suspensions containing tricyclic compounds
NZ331824A (en) *	1994-10-26	2000-01-28	Novartis Ag	use of an unsaturated fatty alcohol to stabilise a macrolide in a pharmaceutical composition
PT2198858E (pt) *	1998-03-26	2011-09-01	Astellas Pharma Inc	Composição farmacêutica de libertação constante que contém um macrólido como o tacrolimus
WO1999055332A1 (en) *	1998-04-27	1999-11-04	Fujisawa Pharmaceutical Co., Ltd.	Medicinal compositions
GB9817064D0 (en) *	1998-08-05	1998-10-07	Fujisawa Pharmaceutical Co	New use
AUPR529701A0 (en) *	2001-05-28	2001-06-21	Fujisawa Pharmaceutical Co., Ltd.	Pharmaceutical composition

2001
- 2001-04-04 GB GBGB0108498.7A patent/GB0108498D0/en not_active Ceased
2002
- 2002-04-03 CN CNB2005100555523A patent/CN100358580C/zh not_active Expired - Fee Related
- 2002-04-03 CA CA2443235A patent/CA2443235C/en not_active Expired - Fee Related
- 2002-04-03 DE DE60217315T patent/DE60217315T2/de not_active Expired - Lifetime
- 2002-04-03 CN CNB028079108A patent/CN1226047C/zh not_active Expired - Fee Related
- 2002-04-03 US US10/473,782 patent/US20040171599A1/en not_active Abandoned
- 2002-04-03 AT AT02735219T patent/ATE350064T1/de active
- 2002-04-03 JP JP2002579016A patent/JP4927310B2/ja not_active Expired - Fee Related
- 2002-04-03 WO PCT/EP2002/003694 patent/WO2002080978A2/en not_active Ceased
- 2002-04-03 EP EP02735219A patent/EP1377315B1/de not_active Expired - Lifetime
- 2002-04-03 AU AU2002310920A patent/AU2002310920A1/en not_active Abandoned
- 2002-04-03 BR BR0208655-7A patent/BR0208655A/pt not_active IP Right Cessation
- 2002-04-03 PT PT02735219T patent/PT1377315E/pt unknown
2007
- 2007-07-24 US US11/880,803 patent/US20070298058A1/en not_active Abandoned
2011
- 2011-05-23 US US13/113,331 patent/US20110224246A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2443235C (en)	2011-03-15
CN100358580C (zh)	2008-01-02
PT1377315E (pt)	2007-02-28
DE60217315D1 (de)	2007-02-15
EP1377315A2 (de)	2004-01-07
GB0108498D0 (en)	2001-05-23
WO2002080978A3 (en)	2003-10-30
US20070298058A1 (en)	2007-12-27
CN1226047C (zh)	2005-11-09
HK1061647A1 (en)	2004-09-30
EP1377315B1 (de)	2007-01-03
JP4927310B2 (ja)	2012-05-09
CN1501814A (zh)	2004-06-02
WO2002080978A2 (en)	2002-10-17
BR0208655A (pt)	2004-03-02
JP2004525169A (ja)	2004-08-19
US20110224246A1 (en)	2011-09-15
AU2002310920A1 (en)	2002-10-21
CA2443235A1 (en)	2002-10-17
US20040171599A1 (en)	2004-09-02
DE60217315T2 (de)	2007-05-31
CN1679962A (zh)	2005-10-12

Legal Events

Date

Code

Title

Description

2007-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1377315

Country of ref document: EP

Publication	Publication Date	Title
TR200103493T2 (tr)	2002-04-22	Metaloproteaz önleyicileri
CY1108532T1 (el)	2014-04-09	Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
DE60038183D1 (de)	2008-04-10	Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
ATE464049T1 (de)	2010-04-15	Pharmazeutische kombinationen von hydrocodon und naltrexon
ATE376832T1 (de)	2007-11-15	Verzögert freisetzende formulierungen von oxymorphon
WO2004030611A3 (en)	2004-06-17	Non-nucleoside reverse transcriptase inhibitors
HUP0202570A1 (hu)	2002-11-28	Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
DE60030741D1 (de)	2006-10-26	Chinazoline verbindungen als heilmittel
ATE402176T1 (de)	2008-08-15	Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
CY1110664T1 (el)	2015-06-10	Ενδορινικες συνθεσετς
SE0101932D0 (sv)	2001-05-31	Pharmaceutical combinations
ATE495187T1 (de)	2011-01-15	Dalda-analoge und ihre verwendung
DK1187803T3 (da)	2005-11-28	Amorfe salpetersyreestere og deres farmaceutiske sammensætninger
MXPA03010054A (es)	2004-04-02	Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
DE60026491D1 (de)	2006-05-04	Melagatran zur behandlung von entzündungen
DE60217315D1 (de)	2007-02-15	Pharmazeutische zusammensetzungen von rapamycines
EE200300129A (et)	2003-06-16	Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
ATE266029T1 (de)	2004-05-15	Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
BG102661A (en)	1999-04-30	Benzo/o/quinolysine derivatives, their preparation and application as 5a-reductase inhibitors
AU2001252419A1 (en)	2001-11-20	Thrombin inhibitors
ES2192789T3 (es)	2003-10-16	Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
DK1181300T3 (da)	2004-01-26	6-O-carbamatketolidderivater
MXPA05007253A (es)	2005-12-14	Sales novedosas de derivados anticonvulsivantes.
MXPA01009032A (es)	2004-11-10	Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.